Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fluprednidene→

Fluprednidene Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2193-87-5
Molecular formula
C22H27FO5
Molecular weight
390.4 g/mol
Drug class
Topical glucocorticoid corticosteroidanti-inflammatory dermatological agent
Mechanism of action
Activates intracellular glucocorticoid receptors and suppresses inflammatory mediator production and immune-cell activity in skin, reducing erythema, oedema and pruritus.
Indications / reported uses
  • Fluprednidene acetate is used in fixed topical combinations with an antifungal such as miconazole for inflammatory skin disease accompanied by fungal infection, according to the specific product authorisation. This entry does not establish a stand-alone fluprednidene indication.

Sources: https://targetpharma.gr/wp-content/uploads/2017/07/Flenazole_EN_PIL_2608201_v2_en.pdf · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fluprednidene Environmental Risk Assessment (ERA) (the Fluprednidene ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.